BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/19/2016 8:57:00 AM | Browse: 1002 | Download: 1812
 |
Received |
|
2015-08-27 08:21 |
|
Peer-Review Started |
|
2015-08-31 14:42 |
|
To Make the First Decision |
|
2015-10-08 16:18 |
|
Return for Revision |
|
2015-10-19 01:38 |
 |
Revised |
|
|
|
Second Decision |
|
2016-06-12 10:11 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2016-06-29 09:54 |
|
Articles in Press |
|
2016-06-29 09:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-07-12 11:55 |
|
Publish the Manuscript Online |
|
2016-07-19 08:57 |
| ISSN |
2218-6255 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Frontier |
| Article Title |
New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Joana Espiga Macedo |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joana Espiga Macedo, MD, Consultant of Medical Oncology, Department of Medical Oncology, Centro Hospitalar de Entre Douro e Vouga, Rua Dr. Cândido de Pinho, 4520-211 Santa Maria Da Feira, Portugal. joanamacedo@hotmail.com |
| Key Words |
Epidermal growth factor receptor-tyrosine kinase inhibitors; Clonal evolution; Non-small cell lung cancer; Acquired resistance |
| Core Tip |
Dramatic changes have occurred in the last decades, concerning the treatment of lung cancer. The knowledge of clinical, pathological and molecular pathways has allowed sub-classifying non-small cell lung cancer (NSCLC), to a point where it has never been reached. The determination of activating mutations of epidermal growth factor receptor (EGFR) has permitted the use of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib in first, second and maintenance setting. However, acquired resistance develops at some stage of the disease, and second generation TKIs have been developed, but with similar results to traditional chemotherapy. With the arrival of third generation TKIs, a selective target mutational personalized therapy has accomplished better response rates, with a lower toxicity profile in phase Ⅰ clinical trials. The question is should NSCLC patients with exon 19del and L858R point mutation in exon 21 be treated differently, once the driver oncogene is known? On the other hand, if patients with acquired resistance with EGFR T790M, should they also be treated targeting this predominant clone? |
| Publish Date |
2016-07-19 08:57 |
| Citation |
Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62 |
| URL |
http://www.wjgnet.com/2218-6255/full/v6/i2/57.htm |
| DOI |
http://dx.doi.org/10.5320/wjr.v6.i2.57 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
